

DAC May 2025 meeting agenda

藥物建議委員會 2025 年 5 月會議議程 (只備英文版)

药物建议委员会 2025 年 5 月会议议程 (只备英文版)

Drugs/ indications: 藥物/ 適應症: 药物/ 适应症	Therapeutic Class: 治療組別: 治疗组别:
1) Alectinib (Alecensa)	Malignant disease and immunosuppression
2) Asciminib (Scemblix)	Malignant disease and immunosuppression
3) Brentuximab Vedotin (Adcetris)	Malignant disease and immunosuppression
4) Cenobamate (XCOPRI)	Central nervous system
5) Dabrafenib/Trametinib (Tafinlar/Mekinist)	Malignant disease and immunosuppression
6) Deucravacitinib (Sotyktu)	Skin
7) Durvalumab (Imfinzi)	Malignant disease and immunosuppression
8) Durvalumab/Tremelimumab (Imfinzi/Imjudo)	Malignant disease and immunosuppression
9) Epcoritamab (Epkinly)	Malignant disease and immunosuppression
10) Evocalcet (Orkedia)	Nutrition and blood
11) Follitropin delta (Rekovelte)	Obstetrics, gynaecology, and urinary-tract disorder
12) Glofitamab (Columvi)	Malignant disease and immunosuppression
13) Glycerol phenylbutyrate (Ravicti)	Nutrition and blood
14) Icosapent ethyl (Vascepa)	Cardiovascular system
15) Mepolizumab (Nucala)	Malignant disease and immunosuppression
16) Mepolizumab (Nucala)	Ear, nose, and oropharynx
17) Momelotinib (Omjjara)	Malignant disease and immunosuppression
18) Nintedanib (Ofev)	Respiratory system
19) Nivolumab (Opdivo)	Malignant disease and immunosuppression
20) Nivolumab/Ipilimumab (Opdivo / Yervoy)	Malignant disease and immunosuppression
21) Olaparib (Lynparza)	Malignant disease and immunosuppression
22) Olaparib (Lynparza)/Bevacizumab	Malignant disease and immunosuppression
23) Pembrolizumab (Keytruda)/Chemotherapy	Malignant disease and immunosuppression (breast)
24) Pembrolizumab (Keytruda)/Chemotherapy	Malignant disease and immunosuppression (lung)
25) Pembrolizumab (Keytruda)	Malignant disease and immunosuppression (lung)
26) Risdiplam (Evrysdi)	Musculoskeletal and joint disease
27) Ritlectinib (Litfulo)	Skin
28) Roxadustat (Evolzio)	Nutrition and blood
29) Ruxolitinib (Jakavi)	Malignant disease and immunosuppression
30) Secukinumab (Cosentyx)	Skin
31) Tepotinib (Tepmetko)	Malignant disease and immunosuppression
32) Tezepelumab (Tezspire)	Respiratory system
33) Zanubrutinib (Brukinsa)	Malignant disease and immunosuppression
34) Zanubrutinib/Obinutuzumab (Brukinsa/Gazyva)	Malignant disease and immunosuppression